Every 10-Q that Foghorn Therapeutics Inc. (FHTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FHTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FHTX filings page.
Foghorn Therapeutics Inc. reported Q2 2026 collaboration revenue of $16.1 million, up from $7.6 million a year earlier, driven largely by a $14.2 million cumulative catch-up adjustment on its Eli Lilly collaboration as the research term approaches scheduled expiration in December 2026. Research and development expenses were $18.5 million and general and administrative expenses $6.4 million, both lower than Q2 2025, reflecting reduced spending on Lilly-partnered programs, discontinued FHD‑286 activities and lower facility costs after relocating to Watertown, Massachusetts.
Net loss for the quarter narrowed to $7.2 million, or $0.10 per share, from $17.9 million, or $0.28 per share, in Q2 2025. For the first six months of 2026, revenue was $19.3 million and net loss $27.1 million. Cash, cash equivalents and marketable securities totaled $167.6 million as of June 30 2026, and management states this balance is expected to fund operating and capital needs for at least 12 months, though additional financing will be required over time to support ongoing development of the Gene Traffic Control® platform and pipeline, including the SMARCA2 program FHD‑909 being developed with Lilly.
In January 2026, Foghorn raised approximately $50.0 million in gross proceeds through a direct offering of common stock, pre‑funded warrants, and two series of equity‑classified warrants, while deferred revenue related to the Lilly collaboration was $229.8 million remaining to be recognized over the development period.
Foghorn Therapeutics reported a first-quarter 2026 net loss of $19.9 million, similar to the prior-year loss of $18.8 million, as it continues investing in its chromatin-targeting oncology pipeline.
Collaboration revenue from its Lilly partnership was $3.3 million, down from $6.0 million, while research and development spending decreased to $18.3 million and general and administrative costs fell to $6.6 million. Cash, cash equivalents and marketable securities totaled $183.6 million as of March 31, 2026, helped by a $50.0 million January 2026 direct equity and warrant financing. Management believes current liquidity will fund operations for at least 12 months, supported by $245.9 million of deferred revenue tied to the Lilly collaboration.
Foghorn Therapeutics (FHTX) reported Q3 2025 results. Collaboration revenue was $8,153,000, modestly above last year. Operating expenses declined year over year as research and development fell to $20,002,000 and general and administrative to $6,652,000. The company posted a net loss of $15,849,000, or $0.25 per share.
Cash and cash equivalents were $89,334,000 and marketable securities were $90,944,000 as of September 30, 2025. Deferred revenue totaled $258,401,000 (current $65,299,000; long‑term $193,102,000), reflecting ongoing performance under the Eli Lilly collaboration. Interest income contributed $2,032,000 in the quarter, and weighted average shares outstanding were 63,029,293. Management states existing cash, cash equivalents and marketable securities will fund operations for at least 12 months.
The Lilly-partnered SMARCA2 program (FHD‑909) remains in early clinical development with cost sharing in place; collaboration revenue recognized depends on progress and costs incurred over time.
Foghorn Therapeutics (FHTX) Q2-25 10-Q highlights:
- Revenue: Collaboration income with Eli Lilly rose 10% YoY to $7.6 m; H1-25 revenue up 13% to $13.5 m.
- Expenses: R&D fell 8% to $21.8 m and G&A fell 6% to $6.9 m, driving a 15% narrower operating loss of $21.1 m.
- Net loss: Q2 loss improved to $17.9 m (-$0.28/sh) from $23.0 m (-$0.45/sh) last year; H1 loss narrowed to $36.8 m (-$0.58/sh).
- Liquidity: Cash & cash equivalents $72.6 m; marketable securities $126.1 m; combined liquid resources $198.7 m. Management expects runway ≥12 months despite $45 m operating cash burn in H1.
- Balance sheet: Deferred revenue declined to $266.6 m as collaboration work progresses; total liabilities $302.9 m exceed assets $226.2 m, producing a $76.7 m shareholders’ deficit.
- Operations: FHD-909 (SMARCA2) transitioned to Lilly with 50/50 cost share; FHD-286 development discontinued (2024). New 10-year Watertown lease signed; Cambridge lease partially reduced, lowering future obligations by $8.5 m.
Key takeaways: Expense discipline and steady milestone revenue trimmed losses, but the pre-commercial company remains cash-burning and carries a negative equity position. Progress of the Lilly collaboration and access to additional capital remain critical catalysts.